ZBIO Zenas Biopharma Earnings and EPS analysis

Relative Growth: Rel. Growth: 10

Relative Strength: Rel. Strength: 40

Relative Valuation: Rel. Valuation: N/A

Relative Profitability: Rel. Profitability: 0

EPS in 2026 (TTM): -$9.1

Last Report Period Date: Mar 31, 2026

As of June 2026, ZBIO's current EPS stands at -$9.1, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of -$8.44, which marks an increase compared to its EPS of -$11.89 in 2024. ZBIO reported an EPS of -$1.46 for the quarterly report ending on Mar 31, 2026.

ZBIO earnings history

Historical annual and quarterly earnings per share (EPS) data for Zenas Biopharma

EPS (TTM)

-$9.1

EPS Growth YoY (Quarterly)

-82.5%

EPS (Quarterly)

-$1.46

EPS Growth (Quarterly)

71.8%

For 2025, Zenas Biopharma's EPS was -$8.44, an increase of 29% from -$11.89 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was -$1.46, showing a 82.5% decrease from the same quarter last year. For the twelve months ending March 2026, the EPS is -$9.1. For the year 2024, the yearly earnings per share was -$11.89, marking an increase of 51% from 2023.

ZBIO earnings chart

ZBIO EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-82.5%

EPS growth YoY

29%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

During the last 12 months, Zenas Biopharma has seen an EPS growth of -82.5% (YoY, quarterly).

ZBIO Earnings Waterfall

Breakdown of revenue, profit and net income for Zenas Biopharma

ZBIO Earnings vs Peers

What are the earnings of ZBIO compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
REGN Regeneron Pharmaceuticals Inc	14.76	5.3%	2.1%	5.7%
GILD Gilead Sciences Inc	17.41	1,700%	23.2%	132.8%
BIIB Biogen Inc	21.02	-21.2%	-25%	-18.7%
AMGN Amgen Inc	23.87	88.1%	5.6%	2.9%
VRTX Vertex Pharmaceuticals Inc	25.97	843.3%	6%	8.2%
SRPT Sarepta Therapeutics Inc	27.77	-388.7%	N/A	N/A
ILMN Illumina Inc	30.44	171.1%	N/A	4.1%
ALNY Alnylam Pharmaceuticals Inc	69.61	209.6%	N/A	N/A
MRNA Moderna Inc	N/A	21.8%	N/A	N/A
ZBIO Zenas Biopharma Inc.	N/A	29%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.